BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection experience antiretroviral-associated liver toxicity more frequently than HIV mono-infected persons. Herein, we report the hepatic safety profile of raltegravir in a relatively large group of HIV/HCV co-infected patients, a population that was poorly represented in the registrational studies. METHODS: Prospective, observational study of all antiretroviral-experienced HIV-infected patients who initiated raltegravir from January 2006 to January 2009 at a reference HIV clinic. Clinical data, laboratory parameters and liver stiffness measured at baseline, week 4 and every 3 months thereafter were collected. Chronic hepatitis C was defined as positive serum HCV-RNA. Grade 1-4 hepatotoxicity was defined following the AIDS Clinical Trials Group definition for liver enzyme elevations (LEEs). A control group of patients who initiated protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) was examined similarly. RESULTS: Data from 218 HIV-infected patients on raltegravir were analysed, 126 HIV mono-infected and 92 HIV/HCV co-infected patients. Any degree of LEEs occurred in 10 (7.9%) HIV mono-infected and 23 (25%) co-infected patients (relative risk 3.1; 95% confidence interval 2.9-3.4; P = 0.002). Severe hepatotoxicity (grade 3-4), however, was only seen in 3 (1.4%) patients, all co-infected with HCV. It occurred at months 1, 15 and 15, respectively. In all three subjects other reasons than raltegravir exposure most likely explained LEEs. Multivariate analysis revealed HCV co-infection as the only independent variable associated with any degree of hepatotoxicity on raltegravir (P = 0.03). Finally, the rate of LEEs in patients on raltegravir was lower than in those who were treated with PIs or NNRTIs. CONCLUSIONS: LEEs are less frequent in patients treated with raltegravir than with other antiretroviral drug classes. However, HIV/HCV co-infected patients treated with raltegravir experienced LEEs more frequently than HIV mono-infected persons. In this series, LEEs in patients treated with raltegravir were uniformly mild and no cases of grade 3-4 hepatotoxicity could be directly attributed to the drug. These results reinforce the overall hepatic safety profile of raltegravir.
BACKGROUND:Patients with chronic hepatitis C virus (HCV) infection experience antiretroviral-associated liver toxicity more frequently than HIV mono-infected persons. Herein, we report the hepatic safety profile of raltegravir in a relatively large group of HIV/HCV co-infectedpatients, a population that was poorly represented in the registrational studies. METHODS: Prospective, observational study of all antiretroviral-experienced HIV-infectedpatients who initiated raltegravir from January 2006 to January 2009 at a reference HIV clinic. Clinical data, laboratory parameters and liver stiffness measured at baseline, week 4 and every 3 months thereafter were collected. Chronic hepatitis C was defined as positive serum HCV-RNA. Grade 1-4 hepatotoxicity was defined following the AIDS Clinical Trials Group definition for liver enzyme elevations (LEEs). A control group of patients who initiated protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) was examined similarly. RESULTS: Data from 218 HIV-infectedpatients on raltegravir were analysed, 126 HIV mono-infected and 92 HIV/HCV co-infectedpatients. Any degree of LEEs occurred in 10 (7.9%) HIV mono-infected and 23 (25%) co-infected patients (relative risk 3.1; 95% confidence interval 2.9-3.4; P = 0.002). Severe hepatotoxicity (grade 3-4), however, was only seen in 3 (1.4%) patients, all co-infected with HCV. It occurred at months 1, 15 and 15, respectively. In all three subjects other reasons than raltegravir exposure most likely explained LEEs. Multivariate analysis revealed HCV co-infection as the only independent variable associated with any degree of hepatotoxicity on raltegravir (P = 0.03). Finally, the rate of LEEs in patients on raltegravir was lower than in those who were treated with PIs or NNRTIs. CONCLUSIONS: LEEs are less frequent in patients treated with raltegravir than with other antiretroviral drug classes. However, HIV/HCV co-infectedpatients treated with raltegravir experienced LEEs more frequently than HIV mono-infected persons. In this series, LEEs in patients treated with raltegravir were uniformly mild and no cases of grade 3-4 hepatotoxicity could be directly attributed to the drug. These results reinforce the overall hepatic safety profile of raltegravir.
Authors: Albert M Anderson; Marina B Mosunjac; Melody P Palmore; Melissa K Osborn; Andrew J Muir Journal: World J Gastroenterol Date: 2010-08-28 Impact factor: 5.742
Authors: Amedeo Capetti; Simona Landonio; Paola Meraviglia; Antonio Di Biagio; Sergio Lo Caputo; Gaetana Sterrantino; Adriana Ammassari; Barbara Menzaghi; Marco Franzetti; Giuseppe Vittorio De Socio; Giovanni Pellicanò; Elena Mazzotta; Alessandro Soria; Marianna Meschiari; Michele Trezzi; Lolita Sasset; Benedetto Maurizio Celesia; Patrizia Zucchi; Sara Melzi; Elena Ricci; Giuliano Rizzardini Journal: PLoS One Date: 2012-07-11 Impact factor: 3.240
Authors: Sergio Barroso; Constanza Morén; Àlex González-Segura; Neus Riba; Joan A Arnaiz; Marcela Manriquez; Gemina Santana; José L Blanco; María Larousse; Montse Loncà; Elisa de Lazzari; Jaume Llopis; Josep Mallolas; Oscar Miró; Xavier Carné; Jose M Gatell; Glòria Garrabou; Esteban Martínez Journal: PLoS One Date: 2019-05-23 Impact factor: 3.240
Authors: Michael Wohlfeiler; Karam Mounzer; Laurence Brunet; Jennifer Fusco; Vani Vannappagari; Lloyd Curtis; Nassrin Payvandi; Michael Aboud; Ricky Hsu; Philip Lackey; Gregory Fusco Journal: Ther Adv Drug Saf Date: 2020-12-08